home.social

#rarediseases — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #rarediseases, aggregated by home.social.

fetched live
  1. 𝗥𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗺𝗮𝗻𝗱 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗠𝗶𝗱𝗱𝗹𝗲 𝗘𝗮𝘀𝘁 𝗶𝘀 𝗲𝗻𝘁𝗲𝗿𝗶𝗻𝗴 𝗮 𝗵𝗶𝗴𝗵 𝗴𝗿𝗼𝘄𝘁𝗵 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗽𝗵𝗮𝘀𝗲!
    The 𝗠𝗶𝗱𝗱𝗹𝗲 𝗘𝗮𝘀𝘁 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗠𝗮𝗿𝗸𝗲𝘁 is expanding as governments improve healthcare access, diagnostics, and specialty drug availability. Rising awareness and advancements in personalized medicine are reshaping patient care outcomes.
    𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: kenresearch.com/middle-east-ra
    #Healthcare #RareDiseases #MiddleEast #PharmaIndustry

  2. Soligenix advances rare disease innovation using platform science to expand its therapeutic pipeline and address unmet medical needs affecting millions. #RareDiseases #Biotech

  3. Soligenix advances rare disease innovation using platform science to expand its therapeutic pipeline and address unmet medical needs affecting millions. #RareDiseases #Biotech

  4. Soligenix reports strong Phase 3 HyBryte data for cutaneous T-cell lymphoma, with response rates exceeding expectations. Interim analysis could accelerate commercialization path. #Biotech #RareDiseases

  5. Soligenix reports strong Phase 3 HyBryte data for cutaneous T-cell lymphoma, with response rates exceeding expectations. Interim analysis could accelerate commercialization path. #Biotech #RareDiseases

  6. Soligenix publishes peer-reviewed HyBryte clinical data demonstrating safety and efficacy for cutaneous T-cell lymphoma treatment. Phase 3 trial interim results expected Q2 2026. #Biotech #RareDiseases

  7. Soligenix publishes peer-reviewed HyBryte clinical data demonstrating safety and efficacy for cutaneous T-cell lymphoma treatment. Phase 3 trial interim results expected Q2 2026. #Biotech #RareDiseases

  8. Soligenix publishes HyBryte clinical data in peer-reviewed journal, highlighting safety and efficacy for cutaneous T-cell lymphoma treatment. Phase 3 interim analysis expected Q2 2026. #Biotech #RareDiseases

  9. Soligenix publishes HyBryte clinical data in peer-reviewed journal, highlighting safety and efficacy for cutaneous T-cell lymphoma treatment. Phase 3 interim analysis expected Q2 2026. #Biotech #RareDiseases

  10. Soligenix's SGX945 receives Promising Innovative Medicine designation from UK MHRA for Behçet's disease, advancing rare disease treatment development. #Biotech #RareDiseases

  11. Soligenix's SGX945 receives Promising Innovative Medicine designation from UK MHRA for Behçet's disease, advancing rare disease treatment development. #Biotech #RareDiseases

  12. Soligenix approaches pivotal 2026 with Phase 3 HyBryte trial for CTCL and SGX945 advancement for Behçet's disease. Multiple clinical catalysts expected. #Biotech #RareDiseases

  13. Soligenix approaches pivotal 2026 with Phase 3 HyBryte trial for CTCL and SGX945 advancement for Behçet's disease. Multiple clinical catalysts expected. #Biotech #RareDiseases

  14. Soligenix enters a pivotal 2026 with key clinical milestones ahead, including Phase 3 FLASH2 trial data for HyBryte in CTCL treatment and progress on SGX945 for Behçet's disease. #Biotech #RareDiseases

  15. Soligenix enters a pivotal 2026 with key clinical milestones ahead, including Phase 3 FLASH2 trial data for HyBryte in CTCL treatment and progress on SGX945 for Behçet's disease. #Biotech #RareDiseases

  16. Soligenix receives EU orphan drug designation for dusquetide in Behçet Disease, securing 10 years of market exclusivity. Phase 2a data demonstrated efficacy and safety. #Biotech #RareDiseases

  17. Soligenix receives EU orphan drug designation for dusquetide in Behçet Disease, securing 10 years of market exclusivity. Phase 2a data demonstrated efficacy and safety. #Biotech #RareDiseases

  18. Soligenix receives EU orphan drug designation for dusquetide in Behcet Disease, securing 10 years of market exclusivity. Builds on Phase 2a efficacy data. #Biotech #RareDiseases

  19. Soligenix receives EU orphan drug designation for dusquetide in Behcet Disease, securing 10 years of market exclusivity. Builds on Phase 2a efficacy data. #Biotech #RareDiseases

  20. Soligenix advances Phase 3 FLASH2 trial for cutaneous T-cell lymphoma with interim analysis expected Q2 2026. Company also secured orphan drug designation for dusquetide in Behçet's Disease. #Biotech #RareDiseases

  21. Soligenix advances Phase 3 FLASH2 trial for cutaneous T-cell lymphoma with interim analysis expected Q2 2026. Company also secured orphan drug designation for dusquetide in Behçet's Disease. #Biotech #RareDiseases

  22. Soligenix's SGX945 earns Promising Innovative Medicine designation in the UK, strengthening its rare disease pipeline. The designation builds on FDA orphan drug recognition for dusquetide. #Biotech #RareDiseases

  23. Soligenix's SGX945 earns Promising Innovative Medicine designation in the UK, strengthening its rare disease pipeline. The designation builds on FDA orphan drug recognition for dusquetide. #Biotech #RareDiseases

  24. Soligenix advances HyBryte clinical credibility with peer-reviewed publication in Expert Opinion on Investigational Drugs, strengthening validation for its cutaneous T-cell lymphoma therapy. #Biotech #RareDiseases

  25. Soligenix advances HyBryte clinical credibility with peer-reviewed publication in Expert Opinion on Investigational Drugs, strengthening validation for its cutaneous T-cell lymphoma therapy. #Biotech #RareDiseases

  26. Soligenix advances Phase 3 CTCL trial with interim analysis expected Q2 2026. Company secures orphan drug designation for dusquetide in Behcet's Disease, strengthening rare disease pipeline. #RareDiseases #Biotech

  27. Soligenix advances Phase 3 CTCL trial with interim analysis expected Q2 2026. Company secures orphan drug designation for dusquetide in Behcet's Disease, strengthening rare disease pipeline. #RareDiseases #Biotech

  28. Soligenix receives European Commission orphan drug designation for SGX945 in Behçet's disease treatment, validating its rare disease pipeline strategy. #Biotech #RareDiseases

  29. Soligenix receives European Commission orphan drug designation for SGX945 in Behçet's disease treatment, validating its rare disease pipeline strategy. #Biotech #RareDiseases

  30. Soligenix reports positive Phase 2 trial results for SGX945 in treating Behçet's disease, offering new hope for patients with rare inflammatory condition #MedicalResearch #RareDiseases

  31. Soligenix reports positive Phase 2 trial results for SGX945 in treating Behçet's disease, offering new hope for patients with rare inflammatory condition #MedicalResearch #RareDiseases

  32. Soligenix reaches 50-patient milestone in Phase 3 HyBryte trial, showing 48% response rate for cutaneous T-cell lymphoma treatment. Promising results signal potential breakthrough in rare disease therapy. #Oncology #RareDiseases

  33. 📊 Global Voxzogo Market Outlook 2026–2030

    Growth driven by rising rare disease investments, genetic research, and demand for disease-modifying therapies.

    Key trends:
    • Targeted genetic therapies
    • Early intervention focus
    • Personalized pediatric treatments

    North America leads the market.

    📥 Get free sample:
    thebusinessresearchcompany.com

    #Healthcare #Pharma #RareDiseases #MarketResearch

  34. 📊 Vpriv Market Outlook to 2030

    Growth driven by rising healthcare spending, rare disease treatment access, and advancements in enzyme therapies.

    Key trends:
    • Personalized dosing strategies
    • Recombinant enzyme tech
    • Long-term disease management

    North America leads the market.

    📥 Get free sample:
    thebusinessresearchcompany.com

    #Healthcare #Pharma #RareDiseases #MarketResearch

  35. Wir starten in die letzte Inhalationswoche.

    Dank den Frühlingsferien müssen wir wenigstens nicht schon 6 oder 7 Uhr anfangen. Also schaffen wir das doch locker 💪😆

    #inhalation #antibiotikum #ataxiateleangiectasia #lungenkrankheit #rarediseases

  36. I’ll attend the #EuroNDD Workshop in Warsaw in April. Anyone around the Fediverse going there as well? —> let’s connect!

    I’m looking forward to present our work at findme2care.de AND hear about all the other projects.

    Also: I’ll be co-hosting an educational session and roundtable discussion titled „Building Patient Registries under the GDPR – The Good, the Bad and the Ugly“ —> there are a few seats left for conference attendees!

    #humangenetics #genetics #RareDiseases #RareDisease #ERN #ERNIthaca #patientregistry

  37. I’ll attend the #EuroNDD Workshop in Warsaw in April. Anyone around the Fediverse going there as well? —> let’s connect!

    I’m looking forward to present our work at findme2care.de AND hear about all the other projects.

    Also: I’ll be co-hosting an educational session and roundtable discussion titled „Building Patient Registries under the GDPR – The Good, the Bad and the Ugly“ —> there are a few seats left for conference attendees!

    #humangenetics #genetics #RareDiseases #RareDisease #ERN #ERNIthaca #patientregistry

  38. PNH & aHUS Market Growth Report 2026–2035 📊

    The Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) market is projected to grow from $5.97B in 2025 to $6.41B in 2026, driven by rising rare disease diagnosis, advanced testing, and next-generation complement inhibitors.

    Get the free sample report:
    thebusinessresearchcompany.com

    #Healthcare #RareDiseases #Biotech #MarketResearch

  39. 💡 A genuine surprise: The active ingredient in #Viagra, sildenafil, helps treat a rare genetic disorder! This unexpected finding has now been uncovered by researchers at #CharitéBerlin. The drug showed positive effects on the course of the disease in six patients with #Leigh syndrome. More on the promising results:

    👉 charite.de/en/service/press_re

    #medicine #science #research #MedMastodon #RareDiseases

  40. 💡 A genuine surprise: The active ingredient in #Viagra, sildenafil, helps treat a rare genetic disorder! This unexpected finding has now been uncovered by researchers at #CharitéBerlin. The drug showed positive effects on the course of the disease in six patients with #Leigh syndrome. More on the promising results:

    👉 charite.de/en/service/press_re

    #medicine #science #research #MedMastodon #RareDiseases

  41. Around 36 million patients in the EU suffer from #RareDiseases. This can have a tremendous influence on their quality of life. What does the EU do to understand and address the challenges?
    See the recent initiatives and actions taken in this field link.europa.eu/BnKbCq
    ---
    nitter.net/EUPublications/stat

  42. February is Rare Disease Month, with Saturday 28 Feb being Rare Disease Day. To highlight this, Disease Models & Mechanisms is promoting its subject collection on rare disease research.

    All articles are Open Access, so free to read and share for everyone: journals.biologists.com/dmm/co

    #RareDiseases #DiseaseModels

  43. RT by @EU_EESC: 🔴 EESC member @MilenaAngel23 #ReportingFromPlenary

    1⃣ @EU_EESC backs European Life Science Strategy >@EUScienceInnov
    2⃣ The 🇪🇺 needs a #RareDiseases action plan
    3⃣ Research & technology are paramount for health

    >@EESC_TEN

    Click here & find out more 👉link.europa.eu/tWWqXg

    🔴 EESC member @MilenaAngel23 #ReportingFromPlenary

    1⃣ @EU_EESC backs European Life Science Strategy @EUScienceInnov
    2⃣ The 🇪🇺 needs a #RareDiseases actio...
    ---
    nitter.net/EESC_PRESS/status/2

  44. We need to do more for patients & their families!

    We call for:
    🧬holistic approach to #RareDiseases;
    🧬stronger EU coordination in research & infrastructure;
    🧬patients organisations and #EUCivilSociety involvement & participation in governance.

    Opinion: link.europa.eu/tWWqXg
    ---
    nitter.net/EU_EESC/status/2024

  45. While CRISPR has opened doors for common genetic conditions, patients with rare diseases often miss out.

    KJ's case showcases the potential for tailored therapies that could change the landscape, overcoming limitations in drug development for low-patient diseases.

    #RareDiseases #Biotech